Cit/CuS@Fe3O4-based and enzyme-responsive magnetic nanoparticles for tumor chemotherapy, photothermal, and photodynamic therapy.
Safe and efficient drug delivery in a controllable fashion, especially remote and repeatable switch of on-demand drug release, is the subject of widespread attention. A kind of magnetic nanoparticles (DOX-Cit/CuS@Fe3O4-NPs) simultaneously consisted of Cit/CuS@Fe3O4and doxorubicin (DOX) was presented. The drug release from DOX-Cit/CuS@Fe3O4-NPs could be successfully triggered by the presence of gelatinase, showing great promise for tumor-targeted drug release through an enzymatic degradation mechanism. Compared with free DOX, DOX-Cit/CuS@Fe3O4-NPs could not only specially deliver Cit/CuS@Fe3O4and DOX into MCF-7 cells, but also could greatly improve the quantity of ROS produced in MCF-7 cells under of 980 nm laser irradiation. DOX-Cit/CuS@Fe3O4-NPs also had highly selective accumulation at tumor tissue of S180tumor-bearing mice, which were along with a magnet near the tumor site. Furthermore, when combined with NIR laser irridation, DOX-Cit/CuS@Fe3O4-NPs showed a higher antitumor efficacy than the individual therapies in vitro and in vivo. This study showed that DOX-Cit/CuS@Fe3O4-NPs could be used as a platform for tumor chemotherapy, photothermal and photodynamic therapy.
1 School of Pharmaceutical Sciences, Henan University of Chinese Medicine, Zhengzhou, PR China.|2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Xiali
X
Zhu
2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Heqing
H
Huang
2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Yingjie
Y
Zhang
2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Huijuan
H
Zhang
2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Lin
L
Hou
2 School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China * Both the authors contributed equally to this work.
Zhenzhong
Z
Zhang
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D003131:Combined Modality Therapy / Q000379:methods; D003300:Copper / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry*; D004058:Diffusion; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D061986:MCF-7 Cells; D058185:Magnetite Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D010778:Photochemotherapy / Q000379:methods*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D003692:Delayed-Action Preparations; D058185:Magnetite Nanoparticles; D003300:Copper; D004317:Doxorubicin; C017846:cupric sulfide
Magnetic nanoparticle; enzyme-responsive; photodynamic therapy; photothermal therapy; tumor targeting